Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced, Refractory Cancer”

1,287 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 1,287 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05262400
What this trial is testing

Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors

Who this might be right for
Breast CancerSolid Tumors
Pfizer 235
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439136
What this trial is testing

Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 40
Early research (Phase 1)Ended earlyNCT05904236
What this trial is testing

Safety and Tolerability of Intravenous Administration of ICVB-1042

Who this might be right for
Patients With Advanced Solid Tumors
IconOVir Bio 17
Early research (Phase 1)Study completedNCT01195311
What this trial is testing

A Dose-escalation Study in Subjects With Advanced Malignancies

Who this might be right for
Solid Tumors and Hematologic Malignancy
Incyte Corporation 52
Early research (Phase 1)Ended earlyNCT05573035
What this trial is testing

Investigate LYL845 in Adults With Solid Tumors

Who this might be right for
MelanomaNon-small Cell Lung CancerColorectal Cancer
Lyell Immunopharma, Inc. 39
Large-scale testing (Phase 3)Ended earlyNCT00416910
What this trial is testing

Combination Chemotherapy With or Without G-CSF in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

Who this might be right for
Chronic Lymphocytic Leukemia
German CLL Study Group 83
Early research (Phase 1)Study completedNCT01404390
What this trial is testing

Japanese BAY80-6946 Monotherapy Phase I Study

Who this might be right for
Neoplasms
Bayer 10
Testing effectiveness (Phase 2)Study completedNCT02335918
What this trial is testing

A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors

Who this might be right for
Squamous Cell Carcinoma of the Head and Neck (SCCHN)Ovarian Carcinoma-Enrollment CompletedColorectal Cancer (CRC)-Enrollment Completed+2 more
Celldex Therapeutics 175
Testing effectiveness (Phase 2)Study completedNCT03108131
What this trial is testing

Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors

Who this might be right for
Skin Squamous Cell CarcinomaAppendix AdenocarcinomaRare Lesion+9 more
M.D. Anderson Cancer Center 49
Large-scale testing (Phase 3)Not Yet RecruitingNCT07653451
What this trial is testing

Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer

Who this might be right for
Esophageal Squamous Cell Carcinoma
Peking University Cancer Hospital & Institute 90
Testing effectiveness (Phase 2)Study completedNCT01828021
What this trial is testing

Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer

Who this might be right for
Breast Cancer
MacroGenics 25
Early research (Phase 1)Looking for participantsNCT07128914
What this trial is testing

A Clinical Study of GO306 in Patients With Advanced Solid Tumors

Who this might be right for
Solid Tumor Malignancies
GeneSail Biotech (Shanghai) Co., Ltd. 32
Testing effectiveness (Phase 2)Looking for participantsNCT07189871
What this trial is testing

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

Who this might be right for
Castration-Resistant Prostate Cancer (CRPC)Colorectal CancerNSCLC (Non-small Cell Lung Cancer)+7 more
Radiopharm Theranostics, Ltd 61
Early research (Phase 1)Study completedNCT01233895
What this trial is testing

Study of AVE1642 Anti-IGF1R Monoclonal Antibody in Patients With Advanced Multiple Myeloma

Who this might be right for
Multiple Myeloma
Sanofi 26
Testing effectiveness (Phase 2)Study completedNCT00096096
What this trial is testing

Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation

Who this might be right for
Chronic Myeloproliferative DisordersGraft Versus Host DiseaseLeukemia+4 more
Fred Hutchinson Cancer Center
Early research (Phase 1)Looking for participantsNCT06088888
What this trial is testing

TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia

Who this might be right for
Chronic Myelogenous Leukemia
Shenzhen TargetRx Co., Ltd. 90
Very early researchUnknownNCT05812677
What this trial is testing

A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Cervical and Endometrial Cancer

Who this might be right for
Cervical CancerEndometrial CancerAdvanced Cancer
Shanghai Yunying Medical Technology 20
Testing effectiveness (Phase 2)Study completedNCT03686488
What this trial is testing

TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaGastric Cancer
H. Lee Moffitt Cancer Center and Research Institute 23
Early research (Phase 1)Ended earlyNCT00385775
What this trial is testing

Study of XIAP Antisense for Advanced Cancers

Who this might be right for
Advanced Cancer
Aegera Therapeutics 30
Early research (Phase 1)Study completedNCT01245205
What this trial is testing

Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer

Who this might be right for
HER2-positive Breast CancerMale Breast CancerRecurrent Breast Cancer+4 more
National Cancer Institute (NCI) 28
Next Page